SCHEMBL1287372

SCHEMBL1287372

COC(=O)c1ccc(CN(C(C)C)S(=O)(=O)c2ccc(Cl)s2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.48
HDAC6 Q9UBN7 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
HDAC2 Q92769 1/20 0.43
BMP1 P13497 3/20 0.42
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
PSEN1 P49768 2/20 0.40
PSEN2 P49810 2/20 0.40
APH1B Q8WW43 2/20 0.40
NCSTN Q92542 2/20 0.40
APH1A Q96BI3 2/20 0.40
PSENEN Q9NZ42 2/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
MLYCD O95822 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1287984 0.90 RAB9A (0.46) RAB9AMAPTSMN1; SMN2POLBBMP1
SCHEMBL15387994 0.88 RAB9A (0.43) RAB9AHDAC6HDAC3HDAC11HDAC8
SCHEMBL15396076 0.85 RAB9A (0.44) RAB9AMAPTSMN1; SMN2POLBBMP1
SCHEMBL1287313 0.80 PSEN1 (0.60) HDAC6HDAC3HDAC11HDAC8MAPT
SCHEMBL10206745 0.78 PSEN1 (0.39) RAB9AHDAC6MAPTHDAC2PSEN1
SCHEMBL1674789 0.77 SLC6A2 (0.41) MAPTSMN1; SMN2ALDH1A1PSEN1PSEN2
SCHEMBL1287491 0.76 KMT2A (0.54) SMN1; SMN2POLBALDH1A1CYP1A2TSHR
SCHEMBL1287307 0.75 RAB9A (0.41) RAB9AHDAC6HDAC3HDAC11HDAC8
SCHEMBL1287977 0.75 PSEN1 (0.52) POLBPSEN1PSEN2APH1BNCSTN
SCHEMBL10205290 0.75 PSEN1 (0.64) HDAC6HDAC3HDAC11HDAC8HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310384-A1 Sulfonamide-Containing Compounds THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-11-21 US disclosed
US-20130310384-A1 Sulfonamide-Containing Compounds THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2013-11-21 US disclosed
WO-2012047926-A2 SULFONAMIDE-CONTAINING COMPOUNDS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-04-12 WO disclosed
WO-2012047926-A2 SULFONAMIDE-CONTAINING COMPOUNDS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310384-A1 Sulfonamide-Containing Compounds BACE1, BACE2, GSAP RAB9A 2338/4885HDAC6 328/4885HDAC3 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.